QualityStocks would like to highlight Oragenics (OTCBB:ORNI), a leading nutraceutical company focused on oral care probiotics for humans and companion pets. The company’s proprietary Evora products and ProBiora3 are currently sold in the United States and international markets. In addition, Oragenics has an exciting pipeline of therapeutic products targeting infectious diseases.
In the company’s news yesterday, Oragenics announced the completion of an independently conducted clinical trial for EvorKids®, the company’s branded product designed to support oral health in children ages 3 to 11.
The randomized, double-blind study enrolled 60 six- to 12-year old children prone to tooth decay/cavity (caries). The study evaluated baseline levels of key oral bacterial species mutans Streptococci and Lactobacilli, which are recognized as risk factors to the development of caries. After four weeks of treatment of EvorKids®, Oragenis reports that results show a statistically significant decrease from baseline of the levels with no adverse events reported during the trial.
Mark Cannon, DDS, the lead author of this independent study, is a faculty member at Northwestern University, an attending physician at Children’s Memorial Hospital, Chicago, and a diplomate of the American Board of Pediatric Dentistry. Dr. Cannon said the clinical study demonstrates that caries-prone children may benefit from the use of probiotics as part of a daily dental hygiene regimen.
John N. Bonfiglio, Ph.D., CEO of Oragenics, noted the results impact on the company itself.
“Oragenics is encouraged by the results of this first independent study in children employing the company’s proprietary blend of oral care probiotics,” Dr. Bonfiglio stated in the press release. “These data agree with previous results obtained from animal and adult human studies conducted by both Oragenics and independent investigators such as Dr. Cannon, and reinforce the claim that the active ingredient in EvoraKids, ProBiora3®, promotes oral health by helping to maintain a naturally balanced oral microflora.”
Oragenics said the trial details and results will be presented on March 21, 2012, at the American Association for Dental Research (AADR) Annual Meeting in Tampa, Fla. The study is titled “DNA-PCR and CRT Results in Children after Probiotic Use,” as part of an entire scientific session of clinical studies related to dental cariology.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
